Methods and compositions for treatment of epileptic disorders
Inventors
Assignees
Interested in licensing this patent?
MTEC can help explore whether this patent might be available for licensing for your application.
Publication Number
US-11903930-B2
Publication Date
2024-02-20
Expiration Date
Abstract
Use of allosteric modulators and/or gaboxadol for the treatment of epileptic disorders in a subject in need thereof.
Core Innovation
The document discloses methods and compositions for treating epileptic disorders using allosteric modulators and/or gaboxadol. The disclosed disorders include status epilepticus and Scn1A-related disorders, and encompass acute repetitive seizures and breakthrough, serial, and cluster seizures.
The allosteric modulators include neurosteroids and other GABA-A related modulators. Examples explicitly referenced include ganaxolone and allopregnanolone, and the document also refers to benzodiazepines and potassium channel openers among the modulators used in the disclosed approaches.
The document links treatment to pharmacokinetic and exposure targets and symptom improvement duration. It describes evaluation using rat Li-Pilo models comparing allopregnanolone, ganaxolone, and gaboxadol for benzodiazepine-resistant status epilepticus, reporting dose-dependent protection and survival, and it characterizes combination planning for synergistic combination evaluation.
Claims Coverage
Not explicitly described in patent.
Not explicitly described in patent.
Stated Advantages
Treats a wide range of epileptic disorders, including status epilepticus and Scn1A-related disorders.
Provides dose-dependent protection and survival in rat Li-Pilo models for benzodiazepine-resistant status epilepticus.
Supports combination/co-administration concepts using separate first/second formulations and exposure targets linked to symptom improvement duration.
Documented Applications
Treatment of status epilepticus, including benzodiazepine-resistant status epilepticus and super-refractory status epilepticus (SRSE) contexts.
Treatment of Scn1A-related disorders, including conditions such as Dravet syndrome and other listed pediatric epilepsy disorders.
Treatment across multiple seizure presentations, including acute repetitive seizures and breakthrough/serial/cluster seizures.
Use in rat Li-Pilo (pilocarpine-induced) models for benzodiazepine-resistant status epilepticus evaluation, comparing allopregnanolone, ganaxolone, and gaboxadol and planning synergistic combination evaluation.
Interested in licensing this patent?